AC Immune Secures $4M Grant to Extend Parkinson’s Trial
Event summary
- AC Immune receives $4M grant from the Goradia Family to extend Part 1 of the Phase 2 VacSYn trial for ACI-7104 in early Parkinson’s disease.
- Extension will assess long-term safety and efficacy of ACI-7104 for an additional 2 years.
- Final data from Part 1 of the VacSYn trial expected in H2 2026.
- ACI-7104 is an anti-alpha-synuclein active immunotherapy targeting early-stage Parkinson’s disease.
The big picture
The grant underscores growing interest in precision therapeutics for neurodegenerative diseases, particularly in early intervention strategies. AC Immune’s focus on alpha-synuclein pathology aligns with broader industry efforts to target misfolded proteins, a key driver in conditions like Parkinson’s. The extension of the VacSYn trial highlights the strategic importance of long-term safety data for regulatory approvals and commercial viability.
What we're watching
- Trial Outcomes
- Whether the extended trial data will confirm ACI-7104’s long-term safety and efficacy in early Parkinson’s disease.
- Funding Impact
- How the $4M grant will accelerate the development timeline for ACI-7104.
- Market Positioning
- The pace at which AC Immune can leverage this trial extension to strengthen its position in the neurodegenerative disease space.